| Name | Atomoxetine hydrochloride |
| Description | Atomoxetine hydrochloride (LY 139603) is the hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels. |
| In vitro | Atomoxetine selectively inhibited the presynaptic uptake of norepinephrine by adrenergic neurons in animals and was also active in an animal model of depression. In microdialysis studies, Atomoxetine had no effect on 5-HTEX levels but increased extracellular norepinephrine levels in the prefrontal cortex by 3-fold. Atomoxetine did not alter DAEX and Fos in the nucleus ambiguus and striatum, but increased DAEX concentrations in the PFC by 3-fold and Fos by 3.7-fold. |
| In vivo | Atomoxetine is a selective inhibitor of norepinephrine reuptake (Ki: 5 nM) and relatively unselective for 5-hydroxytryptamine (Ki: 77 nM) and dopamine transporter protein (Ki: 1451 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (171.34 mM), Sonication is recommended.
H2O : 6.9 mM, Sonication is recommended.
|
| Keywords | Tomoxetine | Norepinephrine (NE) transporter | LY-139603 | LY139603 | DopamineReceptor | Dopamine Receptor | DA transporter | Atomoxetine | 5HTReceptor | 5HT Receptor | 5-HT | (R)-Tomoxetine |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Clozapine N-Oxide | Octopamine hydrochloride | D-Menthol | Citicoline | Amitriptyline hydrochloride | Oxolinic acid | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
